Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis
about
Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1Adipokines and the role of visceral adipose tissue in inflammatory bowel diseaseGut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.Can we protect the gut in critical illness? The role of growth factors and other novel approaches.Proglucagon-derived peptides: mechanisms of action and therapeutic potential.GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.The delay in the development of experimental colitis from isomaltosyloligosaccharides in rats is dependent on the degree of polymerizationGut adaptation and the glucagon-like peptidesThe role of gut hormones in glucose homeostasisUmami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in miceMechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblastsDisruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritisA pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patientsThe role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin/+ mice fed a high-fat dietNutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine.Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats.Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration.Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2.Role of Incretin Axis in Inflammatory Bowel Disease.Discovery, characterization, and clinical development of the glucagon-like peptides.Promising Biomarkers of Environmental Enteric Dysfunction: A Prospective Cohort study in Pakistani Children.Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression.GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis
P2860
Q26752511-C70EEB8D-3199-4233-A0A6-92F9F8186080Q28070229-CBE23E77-F6B1-4590-9DF2-42F92C7A8A25Q33865971-951BBB9D-4CBD-4ECB-812A-EE47D446E9A2Q34014020-3F57E214-A17F-4767-AFBE-1D3E7A932CCBQ34452524-436F4EF5-A3E2-4B95-B84F-5FF4ACB68302Q34494154-8B4E7575-F2C0-4EDC-A25E-F1EA9C662A53Q34500574-9895BABC-7E2A-46EB-8EFA-42E29AFB3AE3Q34526042-78598F28-DCD3-482A-B682-CA69CD14ED67Q35251016-BCF74DEA-64CC-4CAD-BECC-E49EE4F2EE48Q35429613-9D31FF67-AD09-4FB6-87C0-65D9CBC76EE0Q35986076-BD7522CF-1D81-481C-BAD4-913741159EFFQ36063090-F5104CA4-0715-4119-91A7-60E47214A864Q36710034-5620376F-1622-49FA-9CF9-4489F33EC4FFQ37247764-0EE7A6D7-E1EB-4AAA-AD85-8C2D216EFAD6Q38101129-6CD5A5D0-7A77-482A-B0E1-D90D20ABC45EQ41701887-B4F5B767-AB59-41BA-A384-301D6C7598D7Q42468122-FE029183-2A89-42DC-886F-EA788333D0FEQ42507959-BDBDE85B-EBE4-4FF6-8E7B-21897D6EF112Q42721362-8E82F183-B7DA-451D-B292-DE70DE619EDDQ42943394-B04E95CC-035F-4186-BD67-EB1C0F8B7ED6Q43168687-9AC4A6CC-10A0-4DC5-A232-A2B1B4736326Q44891764-327CF6F5-4970-4933-B747-BD4593129202Q47103249-B2007E14-8D88-4FA7-A23C-BB9B61338E08Q47333882-1ABF7460-3C12-437D-B30E-3897726AD230Q50285844-F8B29816-5050-456B-84ED-C342070929A3Q51545833-8E01F1A5-27D8-472B-AF68-E1372F0973B4Q56835462-A7093981-361C-46AA-B709-9449496F49BF
P2860
Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@ast
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@en
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@nl
type
label
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@ast
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@en
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@nl
prefLabel
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@ast
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@en
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@nl
P2093
P2860
P3181
P1476
Glucagon-like peptide 2 decrea ...... hacin-induced murine enteritis
@en
P2093
P2860
P304
P3181
P356
10.1152/AJPENDO.1999.277.5.E937
P407
P433
P577
1999-11-01T00:00:00Z